{
    "organizations": [],
    "uuid": "48b1c2d577e7484a26577305e5a8ca82f917e8a2",
    "author": "",
    "url": "https://www.reuters.com/article/brief-aclaris-says-first-patient-dosed-i/brief-aclaris-says-first-patient-dosed-in-pilot-study-with-ati-502-topical-idUSFWN1S00N6",
    "ord_in_thread": 0,
    "title": "BRIEF-Aclaris Says First Patient Dosed In Pilot Study With ATI-502 Topical",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 23, 2018 / 11:50 AM / Updated 10 minutes ago BRIEF-Aclaris Says First Patient Dosed In Pilot Study With ATI-502 Topical Reuters Staff 1 Min Read \nApril 23 (Reuters) - Aclaris Therapeutics Inc: \n* ACLARIS THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN A PILOT STUDY WITH ATI-502 TOPICAL IN PATIENTS WITH ANDROGENETIC ALOPECIA Source text for Eikon: Further company coverage:",
    "published": "2018-04-23T14:48:00.000+03:00",
    "crawled": "2018-04-23T15:05:05.003+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "updated",
        "minute",
        "ago",
        "say",
        "first",
        "patient",
        "dosed",
        "pilot",
        "study",
        "topical",
        "reuters",
        "staff",
        "min",
        "read",
        "april",
        "reuters",
        "aclaris",
        "therapeutic",
        "inc",
        "aclaris",
        "therapeutic",
        "announces",
        "first",
        "patient",
        "dosed",
        "pilot",
        "study",
        "topical",
        "patient",
        "androgenetic",
        "alopecia",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}